IMV, Inc. (NASDAQ:IMV) Q3 2022 Earnings Convention Name November 11, 2022 8:00 AM ET
Firm Members
Brittany Davison – Chief Accounting Officer
Andrew Corridor – Chief Government Officer
Jeremy Graff – Chief Scientific Officer
Convention Name Members
Brandon Folkes – Cantor Fitzgerald
Joseph Pantginis – H.C. Wainwright & Co.
Paul Stewardson – IA Capital Markets
Operator
Good day and thanks for standing by. Welcome to IMV’s Third Quarter 2022 Earnings Name. Presently, all contributors are in a listen-only mode. After the speaker presentation there will likely be a question-and-answer session. [Operator Instructions]. Please be suggested that at present’s convention is being recorded.
I might now like to show the convention over to Ms. Brittany Davison, Chief Accounting Officer at IMV. Please go forward.
Brittany Davison
Thanks, operator, and good morning, everybody. I am happy to welcome you to IMV’s third quarter 2022 scientific and operational replace convention name. I am joined at present by Andrew Corridor, our CEO; and Dr. Jeremy Graff, our Chief Scientific Officer.
Throughout this name, we are going to talk about our enterprise outlook and make forward-looking statements. Any forward-looking statements made at present are pursuant to and inside the which means of the secure harbor provisions of relevant securities legal guidelines. These feedback are primarily based on present expectations of administration relating to future occasions and working efficiency and shouldn’t be seen as ensures of future efficiency or outcomes.
All forward-looking statements are topic to dangers and uncertainties that would trigger precise outcomes to vary materially. These dangers are mentioned in our steady disclosure paperwork filed in compliance with relevant securities legislation in Canada and the US. The press launch, the MD&A and the monetary statements have all been posted on our web site at imv-inc.com. Should you want to obtain a replica of those paperwork, please don’t hesitate to contact us. Please be aware that we’ll solely take questions from sell-side analysts.
And I’ll now flip the decision over to Andrew to offer an outline of our current highlights and progress. Andrew?
Andrew Corridor
Thanks, Brittany, and welcome everybody to the IMV Q3 operational replace. Quarter three at IMV was all about focus. We considerably accelerated the speed of website enchancment and affected person enrollment for each, VITALIZE and AVALON. We restructured the enterprise to scale back spend on nonclinical investments. That is how we ship near-term shareholder worth.
I’ll start at present’s name with an outline of our enterprise, a refresher on our near-term scientific milestones and a evaluate of current adjustments we have now made right here at IMV. Jeremy will present particulars on the expectations we have now in subsequent yr’s knowledge readouts and introduce the formation of our new scientific advisory board. Then Brittany will come again to offer an outline of our monetary outcomes for the third quarter ended September 30, 2022, earlier than I present closing remarks and we take questions.
I need to emphasize that regardless of the present circumstances, we stay targeted on IMV’s strategic priorities. We’re pushing our lead candidate maveropepimut-S in the direction of registration trials by finishing the 2 ongoing Part 2b scientific proof-of-concept research in DLBCL and ovarian most cancers.
We proceed to advance discussions with scientific companions as validated by our scientific advisers to enhance the supply of their very own immunotherapeutics. To enhance this, we proceed to strengthen the scientific basis of IMV, the DPX expertise with new science, as the info offered this week as SITC confirms. With every new discovery, we’re confirming that the DPX expertise is each differentiated and optimized to ship immune-educating therapies.
On the scientific aspect, activation of websites and enrollment within the VITALIZE Part 2b scientific trial elevated considerably in the course of the third quarter. VITALIZE as a reminder, is designed to additional consider the scientific good thing about maveropepimut-S together with Merck’s anti-PD-1 remedy in sufferers with relapsed and refractory DLBCL. The elevated tempo of enrollment regardless of the variety of aggressive trials on this house speaks to the keenness amongst investigators for MVP-S as a possible remedy for sufferers with DLBCL. As beforehand dedicated, we are going to current scientific response knowledge from the VITALIZE research of the scientific Congress early in 2023.
Recruitment and website activation additionally elevated within the AVALON Part 2b research. The purpose of this research is to additional consider the favorable scientific outcomes noticed in our Part 2a DeCidE research, which evaluated sufferers with recurrent ovarian most cancers receiving maveropepimut-S, an intermittent low-dose cyclophosphamide. Full enrollment of Stage 1 AVALON is anticipated to finish within the third quarter of 2023.
I am going to now flip over to Jeremy, who will current the scientific and scientific highlights from the quarter. Jeremy?
Jeremy Graff
Thanks, Andrew. As Andrew indicated, quarter three for us has been a really productive quarter, each clinically and scientifically. It is actually been 1 / 4 of execution. We’re actively enrolling throughout all 4 scientific trials thus far. VITALIZE continues to enroll properly. As Andrew indicated, we have now picked up enrollment in VITALIZE largely as a result of we aggressively opened new locales in Q2. These locales included websites in Australia, New Zealand and choose international locations within the EU. We’ve got been invited to talk at a convention in Q1 2023, the place we are going to current knowledge on our scientific packages, particularly response charge knowledge for the Stage 1 in VITALIZE.
We have additionally had a major uptick in our ovarian most cancers trial, AVALON. AVALON opened this summer time. We’re activating websites aggressively, and we hope to have our lead website, Stanford, activated with our PI, Oliver Dorigo, within the subsequent few weeks. We count on, enrollment for AVALON will likely be accomplished for the primary stage by the tip of summer time — by the tip of Q3 2023. We’re additionally actively enrolling within the two neoadjuvant research we described beforehand.
The primary is an neoadjuvant research in breast most cancers. These are hormone receptor optimistic HER2-negative sufferers. They’re receiving our drug, maveropepimut-S plus aromatase inhibitors. We’re capable of then seize each, pretreatment and on-treatment tumor biopsy supplies, so we are able to interrogate particularly the consequences that our drug with aromatase inhibitors have on the immunobiology of the tumor and on the tumor website. The primary three sufferers’ value of information are being offered this week at SITC, the Society for the Immunotherapeutic of Most cancers. We’ve got a really sturdy presence at SITC in reality.
For the breast most cancers trial, we may even have a trials in progress poster on the San Antonio Breast Most cancers Symposium in December 2023. The fourth actively enrolling trial is in non-muscle invasive bladder most cancers, NMIBC. Sufferers have been enrolled already on the maveropepimut-S arms and we count on to have the ability to current knowledge from that. Once more, just like the breast most cancers neoadjuvant research, we can interrogate pre and on-treatment tumor tissues in order that we’ll be capable of perceive extra deeply, the science of our lead product, maveropepimut-S.
As I mentioned, this has additionally been a robust scientific quarter. We’ve got marvelous shows at SITC 2022 this week right here in Boston, detailing deeper, richer knowledge as we start to grasp extra absolutely, precisely which immune cell subsets are taking on our product and trafficking our product by means of the immune system. These are revelations for us that can assist us extra sturdy join with scientific neighborhood.
And to that be aware, we’re assembling and finalizing an exquisite Scientific Advisory Board. This will likely be crammed with people who’re acknowledged because the world specialists in most cancers vaccine expertise. The precise announcement for the Scientific Advisory Board ought to occur within the subsequent few weeks.
I’ll now flip this again over to Brittany Davison.
Brittany Davison
Thanks, Jeremy. As reported in our earnings launch issued yesterday, in the course of the third quarter of 2022, we incurred a web loss and complete lack of $8.9 million or $0.11 per share, in comparison with a web lack of $10.4 million or $0.13 per share for the three months ended September 30, 2021. In September, we introduced a workforce restructuring with a purpose to preserve money and focus assets on driving to near-term value-creating milestones. This quarter contains roughly $650,000 of nonrecurring prices associated to this restructuring.
G&A bills decreased by $1.2 million, in comparison with Q3 2021, and this lower in G&A bills was primarily attributable to prices associated to government management adjustments that occurred in Q3 2021, that weren’t replicated within the present quarter, in addition to inventory choice forfeitures related to our September reorganization.
R&D bills for the three months ended September 30, 2022, have been roughly $330,000 larger in comparison with the third quarter in 2021, primarily on account of nonrecurring prices associated to the September restructuring in addition to the development of our Part 2b trials in DLBCL superior ovarian most cancers and our non-muscle invasive bladder most cancers research. These will increase have been principally offset by a lower in basket trial prices as this trial nears completion and MVP-S manufacturing prices.
As of September 30, 2022, the corporate had money and money equivalents of $21.7 million, and money utilized in operations within the first 9 months of the yr was $27 million. In line with our present forecast and assumptions, we count on that our money place stays ample to fund operations into the second quarter of 2023. On account of our current reorganization and value discount measures, we count on our 2023 common money burn per quarter to stay in line with 2022, regardless of forecasted will increase in scientific prices because of the acceleration of our VITALIZE and AVALON trials.
We additionally know that good scientific knowledge is a robust catalyst for institutional funding. With the acceleration of our scientific packages and the power to see the scientific responses in actual time, we imagine, it might create a context favorable to enhance our monetary place.
I’ll now cross it again to Andrew to wrap up and begin the Q&A.
Andrew Corridor
Thanks, Brittany. The anticipated information move is summarized right here. Within the first half of 2023, we are going to full enrollment of the VITALIZE trial and current each the preliminary and the total knowledge set at scientific conferences. Six months behind every of these milestones, we are going to replicate this knowledge move for the AVALON research.
On this atmosphere, possibly greater than ever, scientific knowledge offered on the proper discussion board that confirms significant scientific efficacy validates what we do. We sit up for sharing the small print early in 2023.
Thanks for becoming a member of us at present. And Jason, I am going to now cross again to you for questions.
Operator
[Operator Instructions].
Query-and-Reply Session
Operator
Our first query comes from Brandon Folkes with Cantor Fitzgerald. Your line is open.
Brandon Folkes
Hello, thanks for taking my questions and congratulations on the progress. Possibly simply beginning off on VITALIZE. How do you consider the bar success for that trial? Is it a 75% response charge in PD-1 optimistic sufferers? Or how have you ever set the bar internally, simply given you’ve got this deal with capital allocation? In addition to the — I assume, the Scientific Advisory Board there, too, however simply any shade when it comes to how you consider that internally. After which possibly secondly, how would you describe the partnering atmosphere at present? After which with this restructuring, does that provide you with extra flexibility when it comes to when to see companions for these packages? Is that going to be knowledge dependent? Or are these comparatively well-defined internally and extra about precise worth inflection factors than type of bringing on more money? Thanks very a lot.
Andrew Corridor
Thanks, Brandon. Good to listen to from you. So the primary query was concerning the VITALIZE knowledge. And I believe, you are asking, what’s our expectations on the VITALIZE knowledge, vis-a-vis, possibly what we have proven beforehand in SPiReL? The aim of the trial — and I believe it is vital to remind you of that is — so the purpose is to first replicate what we have seen earlier than in a smaller research, now in a company-sponsored multicenter research that is been validated by the company PI-ed by [indiscernible].
While the excellent eight of 10 sufferers in SPiReL with PD-1 positivity in consequence we definitely search to copy, we additionally want to understand that within the interval publish the research finishing, and now we’re enrolling in VITALIZE, the panorama has modified considerably, and there are cell therapies that weren’t current once we did the primary research. There are different therapeutic regimens, which in impact pushes our remedy again within the regular sequence of remedy. That is to not say, we aren’t terribly assured of the drug’s means to carry out in that house, simply that we’re wanting ahead to, I assume, a later line of remedy and the challenges that include that.
So the actual purpose of VITALIZE is to point out even in a really refractory inhabitants that we nonetheless have the power to show, with an immuno-oncology agent and a mechanism that’s extraordinarily nicely tolerated, that we’re capable of present a profound profit. And we sit up for exhibiting knowledge confirming that in early 2023. Jeremy, is there anything on the DLBCL panorama that is pertinent?
Jeremy Graff
No, I believe, you nailed it.
Andrew Corridor
After which the second query is with respect to the partnering atmosphere and the enterprise improvement atmosphere broadly. Brandon, I believe you’d most likely agree with me that there is been an uptick in M&A in current months, which is all the time a set off for worth throughout the sector. What we’re not seeing is the quantity of licensing and product-related offers. And I believe that is most likely a mirrored image of plenty of corporations, very very like IMV, having depressed valuations primarily based in the marketplace circumstances.
It would not diminish our enthusiasm for enterprise improvement. We nonetheless are persevering with to show round our platform, terrific validation from a scientific entrance. This week at SITC, we in reality, we’re — Jeremy, I believe it is three separate posters we’re presenting at SITC validating — 4 — sorry, posters at SITC, validating the type of worth of what this platform may be. And I believe, we’re realizing now the worth of that within the progress we’re making with collaborative discussions round enterprise improvement.
It is clearly not an optimum marketplace for any actions referring to partnering, however we’re definitely seeing some optimistic traction primarily based on what we proceed to study concerning the DPX platform. After which what we are going to sit up for confirming in early subsequent yr, the worth of the lead product that the platform has created. Did that get to your questions, Brandon?
Brandon Folkes
Good. Very useful. Possibly one follow-up, if I could. You talked concerning the Scientific Advisory Board. Clearly, that is a optimistic. Simply any shade when it comes to timing type of why now, simply type of as we head into these knowledge readouts to get type of further enter from how you bought to individuals, or simply any further shade there when it comes to simply the timing of placing in that board.
Andrew Corridor
And that is a wonderful query, and I am going to have Jeremy take the meat of the query. However one of many issues we’re studying, and that is very in line with what we’re seeing this week at SITC, is that the evolution of the very best scientific considering round methods to greatest ship therapeutics in immuno-oncology appears to be pretty just like the best way that our DPX expertise behaves as we now perceive it.
And so the creation of a Scientific Advisory Board round this level is sort of within the spirit of being now acknowledged as type of a significant platform for the supply of therapeutics on this house which can be turning into rather more vogue, if you’ll. The Advisory Board is absolutely designed to seize a few of that enthusiasm after which assist us drive in the direction of, not simply scientific exploration, however collaboration alternatives. Jeremy, do you’ve got — add to that?
Jeremy Graff
Certain. I believe our scientific group has been actually pushing onerous within the final yr, yr and a half to deepen and broaden our understanding of the best way the drug works. Now that we have got a greater foothold on that, and that is represented in a number of the posters right here at SITC this week, it is simpler for us to exit and seize the creativeness of the very best minds in academia. That is what we have now accomplished. We’ll be capable of announce who these people are.
Within the subsequent few weeks, it is all of the contracts are finalized, however we’re excited to have the ability to try this, share then our knowledge as they emerge not solely from the clinic, but in addition from the labs, and assist develop a future for the expertise and for product on the backs of the discussions with these notable specialists.
Brandon Folkes
Nice. Thanks very a lot. Respect reply for my query. Congrats on the progress.
Jeremy Graff
Thanks.
Operator
Our subsequent query comes from Joe Pantginis with H.C. Wainwright. Your line is open.
Joseph Pantginis
Hey all people good morning. Thanks for taking the questions. One easy query, one dialogue query, and one knowledge timing query. So first, the simple query, I am going to put that in quotations, is I need to talk about your manufacturing experience on two fronts first. What’s your present capability to have the ability to ship on your ongoing research? And what’s your most capability for the variety of doses which you could ship now? And I additionally hyperlink that to potential BD discussions as nicely, the truth that you’ve got these ranges.
Andrew Corridor
So Joe, good to listen to from you. The manufacturing aspect of our enterprise, we handle by means of CMOs. And we have now, I assume, efficiently managed to curate sufficient merchandise and due to the extraordinary shelf life and stability of maveropepimut, to see us by means of clinic. We’re within the means of evolving that to be a industrial prepared product. And that’s ongoing actions as would have been mirrored in our financials for the quarter. And we’re doing that aware that, notably on the ovarian most cancers aspect, that the best way we’re designing the event path in the direction of registration, we have to be industrial prepared in our manufacturing course of sooner reasonably than later.
With respect to the BD ingredient, I assume that I will interpret your query across the novelty of the design and what can occur into the manufacturing so as to add different therapeutics possibly alongside or along with, or as an alternative of survivin or the [indiscernible]. And what we’re attempting to determine now really. Sure, what we’re attempting to do now by means of our manufacturing course of is to simplify the levels in a method that we are able to make the expertise healthier for plug-and-play. What we have now with our lead product is a really considerate and crucial sequence to make the maveropepimut product. In future efforts, we want to simplify that course of in order that we are able to make it extra simplified clearly, however to then shorten the lead time for potential collaborative alternatives. And that’s one thing we have our tech ops and CMC specialists engaged on, as we communicate.
Joseph Pantginis
Received it. That is useful. After which — no, very useful, really. So I am going to ask the timing query first. Simply curious you probably have any steering with regard to the bladder most cancers, neoadjuvant research potential knowledge timing?
Andrew Corridor
Jeremy?
Jeremy Graff
Sure. In order that research goes to develop throughout time. We count on to have the ability to current a number of the first knowledge from the maveropepimut-only cohort early subsequent yr. And in order that knowledge continues to roll out, these are principally translational knowledge with pathology on the tumor website as nicely, at resection, and we’ll be capable of tie these issues collectively. So we’ll count on most likely a few shows all through subsequent yr because the day to evolve and broaden.
Joseph Pantginis
Received it. Received it. So my dialogue level actually is for each Jeremy and Andrew, since you’re on the forefront of the discussions. And I am tying it to your feedback in your ready commentary about enrollment round DLBCL and competitors for sufferers and the truth that you are seeing these good upticks. So I hoped to get even type of anecdotal suggestions from you across the discussions and the way it could also be probably tied to the renewed curiosity round most cancers vaccines and their underlying security?
Andrew Corridor
It is a actually attention-grabbing dialog level. We’re seeing, clearly, within the totality of the market, that there’s an uptick in enthusiasm for mechanisms akin to ours in all areas of oncology. I would not counsel that it is that that is driving the uptick in DLBCL enrollment. What I might counsel is that we have now broadened our websites which can be accessible. And as knowledge is available in, and I believe I’ve guided to this earlier than, we see the info in a method that is successfully dwell. The trial while randomized is unblinded, as do the PI and as do a number of the websites. And because the knowledge is available in, I believe there’s a rising confidence that the remedy has significant profit, and that’s certainly driving the willingness to place very and extra sufferers.
And let’s by no means lose sight of the truth that sufferers in DLBCL that we’re seeing in a scientific setting are sometimes 5, six strains of remedy deep. And having progressed by means of these therapies, they’re on the final restrict of their path by means of most cancers. And there are sufferers that, clearly, physicians are going to be very considerate within the therapies that they launched, simply because if the remedy would not work, the affected person would not do very nicely for very lengthy. And so I believe there’s some a little bit little bit of extra websites up and operating, Joe, after which additionally having the boldness that the therapeutic indices that we have proven beforehand persevering with to be validated by what we’re seeing in clinic now.
Joseph Pantginis
Received it. Respect the suggestions guys.
Andrew Corridor
Good to listen to from you Joe.
Operator
Our subsequent query comes from Paul Stewardson with IA Capital. Your line is open.
Paul Stewardson
Good morning. Thanks for taking our query. Simply calling in for Chelsey. Simply questioning on the smaller trials with the breast and bladder, are you able to give a little bit shade on the competitors for sufferers, what the enrollment type of appears to be like like there, the best way you probably did with VITALIZE?
Andrew Corridor
Sure, I am glad to have Jeremy speak to the smaller trials. And we think about them smaller trials extra as a result of the ends are small, so we’re not speaking about giant affected person numbers. However the trials are targeted extra in a neoadjuvant setting and so they’re very translationally targeted. So the trials require pre and publish biopsies and components equivalent to that, that clearly complicate the sorts of sufferers that may are available in. However Jeremy, do you need to give the steering as to the place we’re at recruiting sensible?
Jeremy Graff
I believe we’re on target in each trials. Within the breast most cancers research, we have now 4 sufferers now in — of the six within the first cohort that we needed. Three of these sufferers are being mentioned right here in SITC this week. After which within the non-muscle invasive bladder most cancers research, we even have 4 sufferers now into that research, and that helps us admire particularly within the bladder most cancers research, what maveropepimut by itself is doing. All of this stuff, as a result of we get the tissue pre and on remedy, we get a very good alternative to interrogate that tissue deeply and actually assess the immunobiology we’re creating within the non-muscle invasive bladder most cancers setting, specifically with maveropepimut as a single agent, we get to very clearly, for the primary time, present proof that maveropepimut is driving this immunobiology all by itself.
So vital research. They’re small research. These are early sufferers. The great thing about these research for the sufferers is, we get to assist them educate their immune system to a most cancers, and hopefully, stop that from ever coming again. However within the near-term, we get to essentially interrogate that tissue in a method that we have by no means had an opportunity to do earlier than.
Paul Stewardson
Nice for that shade. And…
Andrew Corridor
Does that clear your query, Paul?
Paul Stewardson
Sure, it does. And only one extra from me. When it comes to the VITALIZE knowledge, when it comes to the enrollment that you simply’re seeing, are you able to simply give us any preliminary indication of, if that is replicating the SPiReL knowledge when it comes to how closely pretreated and the age of those sufferers? Is that this one thing you are seeing comparable enrollment patterns? Or is there a discrepancy there?
Andrew Corridor
So — and thanks for the query, Paul. I do not assume I might think about it a discrepancy. However we’re seeing sufferers post-cell remedy. We’re seeing sufferers publish a number of the new strains of remedy which have grow to be accessible since we offered the SPiReL knowledge. Clearly, I am not going to information as to the best way we’re responding in these affected person populations, nevertheless it does make the therapeutic problem extra sophisticated when a affected person has progressed by means of extra strains of remedy. So I might say that the panorama we’re working in a DLBCL is extra sophisticated.
However I might additionally say that due to the best way our mechanism appears to — nicely, it isn’t appears to, biologically is totally different and separate to so most of the therapies that they’ve progressed by means of, we’re very assured that even in a refractory affected person, with the biology of maveropepimut and therapeutic efficacy will rise up. And so sure, the panorama has modified, and this will likely be shocking to know on the DLBCL is that sophisticated atmosphere due to the quantity of therapies which can be being developed on this house, that there’s all the time going to be have to be — nicely, there’s all the time going to be a necessity for therapies with a tolerability profile that’s injection-site solely reactions, in any other case no systemic challenges after which a therapeutic index, which demonstrates sturdiness to its efficacy.
So we really feel assured that even in a aggressive panorama and even in an area the place sufferers are possibly extra progressed earlier than they see our remedy, that there’s a nonetheless house for a therapeutic like maveropepimut. Jeremy, do you’ve got any add-ons to that?
Jeremy Graff
I believe it is the essence of the trial at present, now the brand new therapies hit the board for DLBCL sufferers from fracture DLBCL sufferers, is that we’re placing the remedy to the actual take a look at. And we’re nonetheless very assured about what the therapeutic can ship, and we sit up for being and we’ll discuss that early subsequent yr.
Andrew Corridor
Thanks for the query, Paul.
Paul Stewardson
That is nice to pay attention to. Sure, thanks a lot guys.
Operator
There are not any additional questions right now.
Andrew Corridor
Thanks, Michelle. I would be — simply earlier than we shut, I would prefer to say a major thanks to the workforce at IMV. What we do right here issues. Simply keep in mind that each affected person that responds to our remedy is a affected person residing a greater life with most cancers. I admire everybody’s consideration this morning. And Jason, I am going to cross again to you to shut. Thanks.
Operator
This concludes at present’s convention name. Thanks for collaborating. It’s possible you’ll now disconnect.
